ID

33551

Descripción

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02011945

Link

https://clinicaltrials.gov/show/NCT02011945

Palabras clave

  1. 12/12/18 12/12/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

12 de diciembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Chronic Myeloid Leukemia NCT02011945

Eligibility Chronic Myeloid Leukemia NCT02011945

Criteria
Descripción

Criteria

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
confirmed diagnosis of chronic myeloid leukemia in chronic phase or accelerated phase
Descripción

Leukemia, Myeloid, Chronic-Phase | Leukemia, Myeloid, Accelerated Phase

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023474
UMLS CUI [2]
C0023472
with historically documented ph+ cells
Descripción

Cells Philadelphia chromosome positive

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007634
UMLS CUI [1,2]
C0856536
≥2 prior tyrosine kinase inhibitors (tki) therapies for cml
Descripción

Protein tyrosine kinase inhibitor therapy Quantity CML

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0879484
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0023473
currently progressing, resistance to or with a suboptimal response to their most recent therapy
Descripción

Disease Progression | Resistant to Therapy | Response Suboptimal Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C0332325
UMLS CUI [2,2]
C0087111
UMLS CUI [3,1]
C1704632
UMLS CUI [3,2]
C2984009
UMLS CUI [3,3]
C0087111
eastern cooperative oncology group (ecog) performance status (ps) score 0 - 1
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
blast phase cml
Descripción

Blast Phase CML

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0005699
known abl-kinase mutation resistant to dasatinib (e.g. t315i or t315a)
Descripción

BCR-ABL Mutation Resistant to Dasatinib | T315I mutation | Other Coding

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0004891
UMLS CUI [1,2]
C0026882
UMLS CUI [1,3]
C0332325
UMLS CUI [1,4]
C1455147
UMLS CUI [2]
C3889036
UMLS CUI [3]
C3846158

Similar models

Eligibility Chronic Myeloid Leukemia NCT02011945

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Item Group
C1512693 (UMLS CUI)
Leukemia, Myeloid, Chronic-Phase | Leukemia, Myeloid, Accelerated Phase
Item
confirmed diagnosis of chronic myeloid leukemia in chronic phase or accelerated phase
boolean
C0023474 (UMLS CUI [1])
C0023472 (UMLS CUI [2])
Cells Philadelphia chromosome positive
Item
with historically documented ph+ cells
boolean
C0007634 (UMLS CUI [1,1])
C0856536 (UMLS CUI [1,2])
Protein tyrosine kinase inhibitor therapy Quantity CML
Item
≥2 prior tyrosine kinase inhibitors (tki) therapies for cml
boolean
C0879484 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0023473 (UMLS CUI [1,3])
Disease Progression | Resistant to Therapy | Response Suboptimal Therapy
Item
currently progressing, resistance to or with a suboptimal response to their most recent therapy
boolean
C0242656 (UMLS CUI [1])
C0332325 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1704632 (UMLS CUI [3,1])
C2984009 (UMLS CUI [3,2])
C0087111 (UMLS CUI [3,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status (ps) score 0 - 1
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Blast Phase CML
Item
blast phase cml
boolean
C0005699 (UMLS CUI [1])
BCR-ABL Mutation Resistant to Dasatinib | T315I mutation | Other Coding
Item
known abl-kinase mutation resistant to dasatinib (e.g. t315i or t315a)
boolean
C0004891 (UMLS CUI [1,1])
C0026882 (UMLS CUI [1,2])
C0332325 (UMLS CUI [1,3])
C1455147 (UMLS CUI [1,4])
C3889036 (UMLS CUI [2])
C3846158 (UMLS CUI [3])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial